X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
male (9) 9
female (8) 8
adult (7) 7
hepatitis c, chronic - drug therapy (7) 7
middle aged (7) 7
sofosbuvir (6) 6
drug therapy (5) 5
genotype (5) 5
hepatitis (5) 5
treatment outcome (5) 5
antiviral agents - administration & dosage (4) 4
antiviral agents - therapeutic use (4) 4
clinical trials (4) 4
hepacivirus - genetics (4) 4
hepatitis c virus (4) 4
hiv infections - complications (4) 4
infectious disease (4) 4
infectious diseases (4) 4
mortality (4) 4
young adult (4) 4
adolescent (3) 3
aged (3) 3
care and treatment (3) 3
drug therapy, combination (3) 3
education (3) 3
epidemiology (3) 3
health aspects (3) 3
hepatitis c (3) 3
hepatitis c, chronic - complications (3) 3
human immunodeficiency virus--hiv (3) 3
infections (3) 3
product development (3) 3
ribavirin (3) 3
ribavirin - administration & dosage (3) 3
rna, viral - blood (3) 3
uridine monophosphate - analogs & derivatives (3) 3
viral load (3) 3
virus diseases (3) 3
abridged index medicus (2) 2
antiviral agents - adverse effects (2) 2
benzofurans - administration & dosage (2) 2
boceprevir (2) 2
double-blind (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
drug therapy, combination - methods (2) 2
gastroenterology & hepatology (2) 2
genetic aspects (2) 2
genotype & phenotype (2) 2
hcv infection (2) 2
hepacivirus - classification (2) 2
hepatitis c, chronic - virology (2) 2
hiv infection (2) 2
imidazoles - administration & dosage (2) 2
interferon (2) 2
interferon-alpha - administration & dosage (2) 2
interferon-alpha - therapeutic use (2) 2
internal medicine (2) 2
liver cirrhosis (2) 2
liver diseases (2) 2
management (2) 2
medical colleges (2) 2
medicine & public health (2) 2
medicine, general & internal (2) 2
nosocomial infections (2) 2
patients (2) 2
polyethylene glycols - administration & dosage (2) 2
polyethylene glycols - therapeutic use (2) 2
prevention (2) 2
protease inhibitors (2) 2
proteases (2) 2
quinoxalines - administration & dosage (2) 2
recombinant proteins - administration & dosage (2) 2
recombinant proteins - therapeutic use (2) 2
recurrence (2) 2
ribavirin - therapeutic use (2) 2
risk factors (2) 2
simeprevir (2) 2
telaprevir (2) 2
united states (2) 2
uridine monophosphate - administration & dosage (2) 2
uridine monophosphate - therapeutic use (2) 2
viral antigens (2) 2
virus-infection (2) 2
abdomen (1) 1
abt-450/r-ombitasvir (1) 1
administration, oral (1) 1
aids/hiv (1) 1
all-cause mortality (1) 1
alpha 2a (1) 1
alpha-2a plus ribavirin (1) 1
anesthesiology (1) 1
antibiotic resistance (1) 1
antiinfectives and antibacterials (1) 1
antimicrobial agents (1) 1
antimicrobial resistance (1) 1
antiviral agents (1) 1
antiviral therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1087 - 1097
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2015, Volume 2, Issue 8, pp. e319 - e327
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 597 - 605
Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and... 
Infectious Disease | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Drug Therapy, Combination - adverse effects | HIV-1 - isolation & purification | Placebos - adverse effects | Ribavirin - administration & dosage | Adult | Female | Placebos - administration & dosage | Proline - administration & dosage | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | HIV Infections - virology | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | HIV Infections - complications | Aged | Hepacivirus - classification | Interferon-alpha - adverse effects | Medical colleges | Interferon alpha | Clinical trials | HIV (Viruses) | Biological response modifiers | Ribavirin | Viral antigens | Virus diseases | Genetic aspects | Product development | Drug therapy | Hepatitis C virus | HIV infection
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 12/2019, Volume 45, Issue 12, pp. 1703 - 1717
Journal Article
American Journal of Audiology, ISSN 1059-0889, 06/2009, Volume 18, Issue 1, pp. 3 - 6
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.